National Bankshares set a $7.50 target price on Maricann Group (CNSX:MARI – Free Report) in a research report report published on Thursday,BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
Separately, BMO Capital Markets upped their price target on shares of Maricann Group from $5.50 to $5.75 in a research note on Friday, November 29th.
Read Our Latest Research Report on MARI
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Further Reading
- Five stocks we like better than Maricann Group
- What is the Nikkei 225 index?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What is a Death Cross in Stocks?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
